Myosin light chain kinase fragment 11-19 amide  (Synonyms: MLCK(11-19) amide)

Myosin light chain kinase fragment 11-19 amide (MLCK(11-19) amide) is a substrate-specific peptide inhibitor of MLCK. Myosin light chain kinase fragment 11-19 amide inhibits hypotonicity-induced Ca²⁺ entry. Myosin light chain kinase fragment 11-19 amide can be used in the research of human cervical cancer^[1][2].

MLCK^[1]

Myosin light chain kinase fragment 11-19 amide (5 μM) reduces the amplitude and rate of activation of noradrenaline-evoked non-selective cation current (I_cat) in rabbit portal vein myocytes^[1].
Myosin light chain kinase fragment 11-19 amide inhibits swelling-activated taurine transport with an IC₅₀ value of 2.0 µM^[2].
Myosin light chain kinase fragment 11-19 amide (10 µM) inhibits β2-integrin-mediated adhesion in neutrophils treated with KT5720 (25 µM)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

987.16

C₄₀H₇₈N₁₈O₁₁

119386-39-9

KKRAARATS-NH2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Aromolaran AS, et al. Evidence for myosin light chain kinase mediating noradrenaline-evoked cation current in rabbit portal vein myocytes. J Physiol. 2000 May 1;524 Pt 3(Pt 3):853-63.  [Content Brief]

  [2]. Shen MR, et al. Myosin light chain kinase modulates hypotonicity-induced Ca2+ entry and Cl- channel activity in human cervical cancer cells. Pflugers Arch. 2002 May;444(1-2):276-85.  [Content Brief]

  [3]. Chilcoat CD, et al. Tonic protein kinase A activity maintains inactive beta2 integrins in unstimulated neutrophils by reducing myosin light-chain phosphorylation: role of myosin light-chain kinase and Rho kinase. J Leukoc Biol. 2008 Apr;83(4):964-71.  [Content Brief]